Collin Kim
Fortune : 19 929 $ au 31/07/2026
Fortune : 19 929 $ au 31/07/2026
Sang Goo Kim is currently Director at Biocure Technology, Inc. since 2015 and Vice President at Columbia Capital, Inc. since 2008.
Former positions include Independent Director at Gravis Energy Corp.
and Independent Director at First Atlantic Nickel & Cobalt Corp.
from 2015 to 2020.
Education includes an undergraduate degree from Korea University, conferred in 1990.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 04/07/2025 | 1 992 877 ( 9,86% ) | 19 929 $ | 31/07/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| BIOCURE TECHNOLOGY INC. | Directeur/Membre du Conseil | 28/08/2015 |
Columbia Capital, Inc.
Columbia Capital, Inc. Investment ManagersFinance Provides investment advisory services | Corporate Officer/Principal | 01/01/2008 |
| Sociétés | Poste | Fin |
|---|---|---|
Gravis Energy Corp.
Gravis Energy Corp. Other Metals/MineralsNon-Energy Minerals Explores and develops uranium, natural resources | Directeur/Membre du Conseil | - |
| FIRST ATLANTIC NICKEL & COBALT CORP. | Directeur Général | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
First Atlantic Nickel Corp.
First Atlantic Nickel Corp. Other Metals/MineralsNon-Energy Minerals Engages in the acquisition, evaluation, exploration, and development of oil, gas, and mineral resources | Non-Energy Minerals |
Korea University
Korea University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gravis Energy Corp.
Gravis Energy Corp. Other Metals/MineralsNon-Energy Minerals Explores and develops uranium, natural resources | Non-Energy Minerals |
Columbia Capital, Inc.
Columbia Capital, Inc. Investment ManagersFinance Provides investment advisory services | Finance |
Biocure Technology, Inc.
Biocure Technology, Inc. BiotechnologyHealth Technology Develops biopharmaceuticals | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national